David E. Gard

2 papers in the library · 33 citations · publishing 2021

Papers

Sort Most recent Most cited

Evaluating the risk of psilocybin for the treatment of bipolar depression: A review of the research literature and published case studies

Journal of Affective Disorders Reports September 22, 2021 David E. Gard, Mollie Pleet, Ellen Bradley et al. 33 citations

Growing evidence suggests that psilocybin, the active ingredient in hallucinogenic mushrooms, can rapidly and durably improve symptoms of depression, leading to recent breakthrough status designation by the FDA and legalization for mental health treatment in some jurisdictions. Depression in bipolar disorder is associated with significant morbidity and has few effective treatments. However,...

DOI: 10.1016/j.jadr.2021.100240 Full text Psilocybin Depression economics Bipolar disorder Psychotherapist +3

Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Systematic Review of Published Case Studies

medRxiv April 7, 2021 David E. Gard, Mollie Pleet, Ellen Bradley et al. preprint

Abstract Objective: Given the treatment limitations of depression in bipolar disorder, we evaluated the known risks of using psilocybin (and similar substances) in this population, including a systematic assessment of published case histories, to assess the risk of psilocybin as a treatment of depression in bipolar disorder. Data Sources: A comprehensive search of case studies published through...

DOI: 10.1101/2021.04.02.21254838 Full text